Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Gilead Sciences, Inc. : FDA Panel Backs Gilead's HIV 'Quad' Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/11/2012 | 09:06pm CET
   By Jennifer Corbett Dooren 
   Of  
 

A federal advisory panel Friday backed an experimental Gilead Sciences Inc. (GILD) HIV medicine known as the Quad.

The company is seeking approval from the Food and Drug Administration to market the product, which combines four active ingredients into one pill, meant to be taken once daily.

The medicine was reviewed on Friday by the agency's antiviral drugs advisory panel, which is made up of non-FDA medical experts. The panel voted 13 to 1 on a question that asked if the submitted clinical data supported approval of the drug. The panel vote amounts to a recommendation that the FDA approve the drug. The agency usually follows panel recommendations but isn't required to. The FDA is expected to make a decision by the end of August.

Quad is a combination of four active ingredients in one pill. It combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat.

Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller.

-By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
09:12a GILEAD SCIENCES : adds to CAR-T assets with Cell Design Labs buyout
01:31a GILEAD SCIENCES : Kite Announces Data From ZUMA-3 Study of KTE-C19 in Adult Pati..
12/11 GILEAD SCIENCES : Today’s Research Reports on Stocks to Watch: Gilead Sciences a..
12/11 GILEAD SCIENCES : and Kite to Acquire Cell Design Labs
12/11 GILEAD SCIENCES : Hookipa raises EUR 50 million series C
12/11 GILEAD SCIENCES : acquires CDL for $567m
12/11 GILEAD SCIENCES : US stocks end higher on Friday on the back of strong jobs data
12/11 GILEAD : Kite Reveals Long-Term Data From Pivotal ZUMA-1 Study Of Yescarta
12/10 GILEAD SCIENCES : acquires CDL for $567m
12/10 GILEAD SCIENCES : Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yes..
More news
News from SeekingAlpha
10:03a GILEAD : Avoid 2017's Frustrations
06:13a YOUR DAILY PHARMA SCOOP : Gilead Remains Long-Term Story, Argenx Rallies, Bluebi..
12/11 YOUR DAILY PHARMA SCOOP : Celgene Upside, Erytech Tumbles, Novartis Neulasta Bio..
12/10 GILEAD DOUBLES DOWN ON CAR-T : Updates To Thesis
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
Financials ($)
Sales 2017 25 816 M
EBIT 2017 15 661 M
Net income 2017 10 511 M
Debt 2017 12 742 M
Yield 2017 2,71%
P/E ratio 2017 9,75
P/E ratio 2018 12,72
EV / Sales 2017 4,33x
EV / Sales 2018 4,91x
Capitalization 99 094 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 85,7 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.55%99 094
REGENERON PHARMACEUTICALS1.78%40 969
VERTEX PHARMACEUTICALS88.38%35 831
GENMAB1.79%11 452
BLUEBIRD BIO INC172.12%9 249
EXELIXIS, INC.80.42%7 816